Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

32.7K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
32.7K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.1K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

1.9K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
1.9K
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

3.2K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.2K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

3.4K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
3.4K
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.9K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetically determined increase in apolipoprotein C-III (APOC3 gain-of-function) delays very low-density lipoprotein clearance in humans.

Atherosclerosis·2025
Same author

Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects.

Journal of internal medicine·2019
Same author

Interaction of chylomicron remnants and VLDLs during ultracentrifuge separation based on the Svedberg flotation rate - Authors' response.

Journal of internal medicine·2019
Same author

Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics.

Journal of internal medicine·2019
Same author

Hepatitis C virus and atherosclerosis: A legacy after virologic cure?

Clinics and research in hepatology and gastroenterology·2016
Same author

Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly.

Diabetologia·2008
Same journal

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026
Same journal

The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

European heart journal·2026
Same journal

Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

European heart journal·2026
Same journal

Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis.

European heart journal·2026
Same journal

Myths and misconceptions about high-sensitivity C-reactive protein as a marker of residual inflammatory risk.

European heart journal·2026
Same journal

Vascular Ehlers-Danlos syndrome: should we treat asymptomatic patients?

European heart journal·2026
See all related articles

Related Experiment Video

Updated: Nov 3, 2025

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

156

Overview of fenofibrate

C J Packard1

  • 1Institute of Biochemistry, Glasgow Royal Infirmary University NHS Trust, U.K.

European Heart Journal
|March 31, 1998
PubMed
Summary
This summary is machine-generated.

Fenofibrate effectively lowers triglycerides and LDL cholesterol while raising HDL cholesterol. Its mechanism involves activating PPAR receptors, reducing apolipoprotein C-III, and enhancing triglyceride-rich particle catabolism.

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.4K
FIBS-enabled Noninvasive Metabolic Profiling
09:16

FIBS-enabled Noninvasive Metabolic Profiling

Published on: February 3, 2014

10.0K

Related Experiment Videos

Last Updated: Nov 3, 2025

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

156
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.4K
FIBS-enabled Noninvasive Metabolic Profiling
09:16

FIBS-enabled Noninvasive Metabolic Profiling

Published on: February 3, 2014

10.0K

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cardiovascular Medicine

Background:

  • Fenofibrate is a lipid-lowering agent that reduces triglycerides and LDL, and increases HDL.
  • It corrects atherogenic lipoprotein phenotypes common in coronary heart disease.
  • Previous research indicated its effects on lipid metabolism.

Purpose of the Study:

  • To elucidate the molecular mechanism of fenofibrate's lipid-lowering action.
  • To understand how fenofibrate influences lipoprotein metabolism at the molecular level.

Main Methods:

  • Investigated fenofibrate's interaction with peroxisome proliferator activated receptor (PPAR).
  • Analyzed the downstream effects on apolipoprotein C-III synthesis and lipoprotein catabolism.

Main Results:

  • Fenofibrate binds to PPAR, initiating a cascade that reduces hepatic apolipoprotein C-III synthesis.
  • Suppression of apolipoprotein C-III enhances the lipolysis and clearance of triglyceride-rich particles.
  • Observed shifts in LDL subfractions, reducing small, dense LDL particles.

Conclusions:

  • Fenofibrate's primary action is through PPAR activation, leading to reduced apolipoprotein C-III.
  • This mechanism enhances the catabolism of triglyceride-rich lipoproteins, improving lipid profiles.
  • Fenofibrate offers a targeted approach to managing dyslipidemia and associated cardiovascular risks.